ENDPOINTS

NextCure inks ADC deal with Simcere Zaiming

NextCure will be paying up to $745 million for the ex-Greater China rights to an early-stage antibody-drug conjugate developed by a Shanghai-based drug developer. Simcere Zaiming's asset, called SIM0505, targets CDH6. It’s currently in a ...

Jun 16, 2025 - 15:20
 0
NextCure inks ADC deal with Simcere Zaiming
NextCure will be paying up to $745 million for the ex-Greater China rights to an early-stage antibody-drug conjugate developed by a Shanghai-based drug developer. Simcere Zaiming's asset, called SIM0505, targets CDH6. It’s currently in a ...
Read More

Tags:

Previous Article

Powerful solar flare erupts from sun triggering radio blackouts across North Ame...

Next Article

What is uranium enrichment and how is it used for nuclear bombs? A scientist exp...

Related Posts

#ASCO25: Kura spells out pivotal AML trial win as it gears up to compete with Syndax

#ASCO25: Kura spells out pivotal AML trial win as it ge...

May 23, 2025  0

Pfizer joins PD-1xVEGF race with $1.25B upfront to Chinese biotech 3SBio

Pfizer joins PD-1xVEGF race with $1.25B upfront to Chin...

May 20, 2025  0

FDA approves Liquidia's inhaled hypertension drug in two settings

FDA approves Liquidia's inhaled hypertension drug in tw...

May 27, 2025  0